| Complication | Evidence | PMID |
| Retinopathy | 1. The present findings reveal that diabetes-induced retinal inflammation stems from downregulation of the AMP-activated protein kinase (AMPK) pathway, leading subsequently to SIRT1 deactivation and NF-KB activation. The data also suggest the potential use of the AMPK activator resveratrol as a therapeutic agent for diabetic retinopathy. | 22058332 |
| Cardiovascular | 1. SIRT1 therefore has a critical role and holds exciting prospects for new therapeutic strategies that can offer reparative processes for cardiac, vascular, and nervous system degenerative disorders as well as targeted control of aberrant cell growth during cancer. | 25815111 |
| Atherosclerosis | 1. Decreased expression of SIRT1 in artery may be involved in the initiation and development of diabetic atherosclerosis | 21810449 |
| Nephropathy | 1. SIRT1 rs10823108 and FOXO1 rs17446614 are responsible for genetic susceptibility to diabetic nephropathy. | 28860538 |
| Dyslipidemia | 1. SIRT1 has been suggested as putative therapeutic target in multiple age-related diseases including type 2 diabetes and dyslipidemias. | 28860538 |
| Neuropathy | 1. Our previous results demonstrated that sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, alleviates neuropathic pain in type 2 diabetes mellitus rats. | 28860538 |
| Insulin resistance and inflammation | 1. Myeloid-specific deletion of Sirt1 promotes macrophage infiltration into insulin-sensitive organs and aggravates tissue inflammation. | 23284689 |
